Медицинский совет (Oct 2020)

Routine correction disadvantages of iron deficiency anemia in pregnant women, women in labor and puerperas (a retrospective study based at the State Budgetary Healthcare Institution of Nizhny Novgorod Region “Dzerzhinsk Perinatal Center”)

  • N. A. Barkovskaya,
  • N. Yu. Katkova,
  • V. Ya. Vartanov,
  • O. V. Kurkina

DOI
https://doi.org/10.21518/2079-701X-2020-13-14-23
Journal volume & issue
Vol. 0, no. 13
pp. 14 – 23

Abstract

Read online

Introduction. Iron deficiency (ID) is in almost 90% of pregnant woman by the third trimester, persisting in 55% of cases after childbirth. This study aims identification of deficiencies in the routine diagnostics and correction of iron deficiency anemia (IDA) in pregnant women, women in labor and postpartum.Methods. the study included 150 pregnant women from 18 to 43 years old, in whom iron therapy during pregnancy and the postpartum period analyzed in a complex of blood-saving technologies.Results. Serum ferritin (SF) detected only in 45% of pregnant women with anemia. In the first trimester, mild anemia diagnosed in 10% of women, moderate - in 0.6%; in the second trimester - in 47.3% and 1.2%, respectively. In the third trimester, mild anemia was in 94% of patients, moderate - in 4%. Correction of IDA in 94% of cases carried out with oral iron. In the postpartum period, all women have IDA: mild anemia in 82.7%, moderate in 15.3%, severe in 2% of cases. Mild anemia treated with oral iron, moderate - with intravenous iron in 61%, in other cases used oral iron.Conclusion. An increased severity of IDA before childbirth, in spite of it’s correction during pregnancy; it is necessary to diagnose anemia by SF in all pregnant women, with an assessment of the oral iron therapy response by hemoglobin and tolerance; in the absence of a result, intravenous non-dextran iron is indicated in the required calculated dose. Complex correction of obstetric blood loss and postpartum anemia by autoerythrocytes, blood coagulation factors and rational IDA therapy with non-dextran high-dose intravenous iron will allow us to implement restricting approach of the use of donor blood components.

Keywords